美沙拉嗪治疗肠易激综合征的Meta分析

Meta-analysis of mesalazine for irritable bowel syndrome

目的:评估美沙拉嗪治疗肠易激综合征的疗效及安全性.方法:从中国知网数据库、中国维普数据库、万方数据库、Pub Med、MEDLINE、Cochrane Library等在线数据库检索美沙拉嗪治疗肠易激综合征的随机对照试验,并对纳入文献进行质量评价和数据提取进行Meta分析.结果:按照纳入标准及剔除标准,共纳入13篇文献1349例病例进行Meta分析.结果显示美沙拉嗪治疗肠易激综合征临床症状改善的总有效率(P<0.01),及腹痛(P<0.01)、腹泻(P<0.01)、大便性状异常改善(P<0.05)的总有效率均显著高于对照组,美沙拉嗪组治疗后腹痛评分显著低于对照组(P<0.01),而不良反应的发生率2组之间无显著性差异(P=0.26).结论:美沙拉嗪治疗肠易激综合征有显著的疗效,可改善患者腹痛、腹泻及大便性状异常,能降低患者腹痛程度,且有良好的安全性.

AIM： To evaluate the efficacy and safety of mesalazine for irritable bowel syndrome.METHODS： Online databases, including China National Knowledge Infrastructure database（CNKI）, VIP database, Wanfang database, Pub Med, MEDLINE and Cochrane Library, were searched for randomized controlled trials of mesalazine for irritable bowel syndrome. After assessing the methodological strength, we extracted relevant data from the includedstudies to conduct a meta-analysis.RESULTS： Based on the inclusion and exclusion criteria, 13 randomized controlled trails with a total of 1349 patients were included in this study. Clinical remission rate and abdominal pain score were significantly improved in the mesalazine group when compared with the control group. However, there was no significant difference in adverse reactions between the two groups.CONCLUSION： Mesalazine could significantly improve clinical outcome and relieve abdominal pain of patients with irritable bowel syndrome, without significant adverse reactions.